Patient centric sampling means getting a usable biological sample from a person wherever that person already is, with as little burden on them as possible. It is a design requirement, not a device category. Teams that treat it as a device category pick hardware first and discover the mismatch after the packaging is printed.
The definition, and why the loose version causes problems
The Patient Centric Sampling Interest Group describes patient centric sampling as obtaining high quality biological samples from humans at any time and in any location, with the patient’s needs and comfort at the front of the design. The matrices in scope are broad: blood, plasma, serum, urine, stool, saliva. So are the device categories: samplers, lancets, swabs, urine collection systems.
Read that twice and notice what it does not say. It does not say fingerstick. It does not say home. It does not say dried blood. Those are implementations. Patient centric sampling is the requirement those implementations are trying to satisfy.
Programs get into trouble when they invert the order. A team selects a device, usually a small capillary device that photographs well, then works backward to find an assay that tolerates it. That sequence fails late, and it fails after money is committed to tooling and print.
What patient centric sampling is not
It is not automatically a home collection kit. A patient centric option can be a fingerstick at a retail pharmacy, a collection at a workplace clinic, or a mobile phlebotomist at a kitchen table. All three cut patient burden. Only one of them needs a kit.
It is not a way around validation. Changing the specimen type changes the analytical question, and the laboratory owns that question. The UK recommendations for the validation and adoption of capillary blood testing within the routine clinical laboratory, published in Annals of Clinical Biochemistry in May 2026, puts it plainly. Accredited laboratories that want to report capillary results have to run their own comparison studies, and most assay manufacturers do not list capillary blood in their instructions for use, so the validation burden sits with the laboratory rather than the device maker.
It is not cheaper by default. Less volume means tighter tolerances, more rejected samples, and more re-collection. Re-collection is the line item that quietly decides whether the program pencils.
Three questions that decide fit
Answer these before anyone scopes a kit.
Will the assay run on the matrix and the volume you will actually get
Not the volume on the device datasheet. The volume a real person produces on a cold morning, on a second attempt, with one hand. Ask the laboratory for the minimum volume that clears analyzer dead volume plus one repeat, and get it in writing. If the method needs plasma and the collection yields whole blood, there is a separation step to solve, either in the field or at accessioning, and someone has to own it.
Can the result be compared to what your reference interval assumes
Capillary blood is not venous plasma. For some analytes the gap is small. For others it is wide enough to change how the number reads. The International Association of Therapeutic Drug Monitoring and Clinical Toxicology published a guideline in February 2026 on converting capillary microsampling concentrations to plasma concentrations, and the reason it needed writing is that there is no single conversion factor that holds across analytes. If the plan is to report against a venous reference interval, comparability work is the critical path. Packaging is not.
Can an untrained person collect it correctly on the first try
One attempt. No supervision. No spare device in the box unless you put one there. Watch ten people who do not work for you run the process end to end. Count how many read the instructions, how many warm the hand, how many squeeze the finger, and how many fill to the line. That failure rate is the program’s real yield, and it is where the instructions for use, not the device, do most of the work.
Where it fits well
- Repeat measurement of a stable analyte, where the burden of clinic visits is the main barrier to adherence.
- Populations with poor venipuncture access, including remote areas, needle-averse patients, older patients, and patients with difficult veins.
- Trial designs with decentralized elements. FDA’s final guidance on conducting clinical trials with decentralized elements treats remote collection as a legitimate design choice carrying its own obligations, which means the sampling plan has to be written before enrollment rather than improvised during it.
- Screening programs where the realistic alternative is no sample at all.
Where it does not fit
- Analytes that are unstable at ambient temperature across the transit time your return path actually takes, not the transit time the carrier advertises.
- Assays that need a large volume, or a separated fraction, with no field-workable separation step.
- Any workflow where an out-of-range result triggers an urgent clinical action and the return path cannot meet that clock.
- Programs whose main driver is cost per result. If patient burden is not the binding constraint, a mobile phlebotomy network or a retail draw network usually wins on cost per usable result once re-collection is priced in.
That last answer points away from building a kit, and it is the right answer more often than the market admits.
Sorting devices by mechanism, not by brand
There is no useful shopping list, because the right device depends on the assay. Sorting candidates by mechanism is more useful than sorting them by vendor.
- Lancet into an open microtube. Cheap, familiar to laboratories, and highly dependent on user technique. A standard fingerstick microtube such as a BD Microtainer sits here.
- Metered capillary collection into a sealed tube or cartridge. The device controls volume, which narrows variability at the cost of unit price and box space. Self-collection devices such as RedDrop sit in this group.
- Volumetric absorptive tips that take a fixed volume onto a dry substrate. Ambient shipping gets simpler. The extraction and recovery work moves to the laboratory.
- Dried blood spot cards. The longest history and the most published data, with variability driven by spot quality and hematocrit.
- Push-button collectors that apply negative pressure to the upper arm. Better patient experience, higher unit cost, larger footprint in the box.
- Non-blood matrices. Saliva tubes with stabilizing buffer, urine cups with preservative, dry swabs. These get skipped more often than they should when the analyte allows them.
Regulatory status for any device or matrix, and what you are permitted to claim about it, belongs to your own regulatory lead. Confirm it in writing before it reaches a label, an insert, or a web page.
Practical takeaways
- Write the requirement, not the device. “Patients produce a comparable result at home, monthly, delivered to the laboratory within 48 hours” is a requirement. “Uses a microsampling device” is not.
- Get the laboratory’s minimum viable volume in writing, with one repeat included.
- Treat comparability to your reference interval as the critical path, and start it before packaging design.
- Test the instructions on strangers, not staff, and count the failures.
- Price the program on cost per usable result, not cost per kit.
- Confirm regulatory status and claim language with your own regulatory lead before anything is printed.
- If patient burden is not the binding constraint, do not build a kit.
Related reading: capillary collection or venipuncture covers how to choose between the two once you know self-collection fits, and how to choose a preservation medium covers what stabilizes the sample after it leaves the patient.
